Lilly Announces Dr. Lechleiter’s Return

barbara.lempert INDIANAPOLIS, July 8, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., has returned to his duties ...

ADA roundup: Eli Lilly, Sanofi, Novo vie for center stage at diabetes confab

Ryan McBride We're put together snippets from the top ADA stories over the weekends with links to the full articles below. If you haven't done so already, please open the special ...

Boehringer, Lilly tout PhIII results for another SGLT2 drug

Ryan McBride FierceBiotech News

You Just Won… Lilly Fights Scam Artists Over Use Of Its Name

esilverman You know you have a popular brand when scam artists are using it to bolster their schemes. But Eli Lilly, which says scamsters are using its well-known moniker and ...

Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests

barbara.lempert INDIANAPOLIS, June 19, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) today issued an alert about two illegal scams, purportedly using the name of the company ...

Novo’s quick-selling Victoza threatened by Lilly diabetes hopeful

Tracy Staton Novo Nordisk's current blockbuster, Victoza, continues to rack up impressive sales increases despite the FDA's refusal to approve the Danish drugmaker's ...

Eli Lilly wraps $247M deal for PhII diabetes drug

John Carroll Eli Lilly is stepping in to take control of an experimental diabetes drug from Canada's Transition Therapeutics, paying $ 7 million upfront and promising up to $ ...

Lilly Ends Phase II Alzheimer’s Study Over Liver Problems

barbara.lempert Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer’s Disease Decision ...

Eli Lilly racks up another Alzheimer’s failure after BACE drug sparks safety fears

John Carroll FierceBiotech News

Lilly blockbuster Alimta burned by more disappointing news

Eric Palmer There is bad news out of ASCO for Eli Lilly's ($ LLY) Alimta, its blockbuster lung cancer drug that is already under a patent assault by Teva Pharmaceutical Industries ...

Lilly backs $50M launch of public/private biotech research institute

John Carroll Eli Lilly and Roche Diagnostics have joined an industry consortium that will help launch a new research institute in Indiana that plans to hire a staff of about 100 investigators ...

Merck, Lilly, Pfizer top $1B doc-payments list

Tracy Staton Drugmakers forked over more than $ 1 billion to doctors last year, significantly more than reported in 2011. And that's only the amounts we know about. According to ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS